Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
May 2024
|
| In: |
Journal of thoracic oncology
Year: 2024, Volume: 19, Issue: 5, Pages: e5-e6 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2024.01.020 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2024.01.020 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086424000613 
|
| Author Notes: | Binghao Zhao, Longping Yao, Wenbin Ma |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 190943373X | ||
| 003 | DE-627 | ||
| 005 | 20241205222330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2024.01.020 |2 doi | |
| 035 | |a (DE-627)190943373X | ||
| 035 | |a (DE-599)KXP190943373X | ||
| 035 | |a (OCoLC)1475647925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zhao, Binghao |d 1994- |e VerfasserIn |0 (DE-588)1328556751 |0 (DE-627)1887983023 |4 aut | |
| 245 | 1 | 0 | |a Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC |c Binghao Zhao, Longping Yao, Wenbin Ma |
| 264 | 1 | |c May 2024 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 6. Mai 2024 | ||
| 500 | |a Gesehen am 25.11.2024 | ||
| 700 | 1 | |a Yao, Longping |d 1991- |e VerfasserIn |0 (DE-588)1280535644 |0 (DE-627)1833799747 |4 aut | |
| 700 | 1 | |a Ma, Wenbin |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology |d Amsterdam : Elsevier, 2006 |g 19(2024), 5 vom: Mai, Seite e5-e6 |h Online-Ressource |w (DE-627)508331986 |w (DE-600)2223437-8 |w (DE-576)336961553 |x 1556-1380 |7 nnas |a Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:5 |g month:05 |g pages:e5-e6 |g extent:2 |a Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jtho.2024.01.020 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1556086424000613 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241125 | ||
| 993 | |a Editorial | ||
| 994 | |a 2024 | ||
| 998 | |g 1280535644 |a Yao, Longping |m 1280535644:Yao, Longping |d 50000 |e 50000PY1280535644 |k 0/50000/ |p 2 | ||
| 998 | |g 1328556751 |a Zhao, Binghao |m 1328556751:Zhao, Binghao |d 60000 |e 60000PZ1328556751 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN190943373X |e 4622081504 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"190943373X","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online verfügbar: 6. Mai 2024","Gesehen am 25.11.2024"],"title":[{"title":"Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC","title_sort":"Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC"}],"person":[{"family":"Zhao","given":"Binghao","display":"Zhao, Binghao","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Yao, Longping","roleDisplay":"VerfasserIn","given":"Longping","family":"Yao"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Ma, Wenbin","given":"Wenbin","family":"Ma"}],"relHost":[{"title":[{"subtitle":"JTO ; official publication of the International Association for the Study of Lung Cancer","title":"Journal of thoracic oncology","title_sort":"Journal of thoracic oncology"}],"pubHistory":["1.2006 -"],"titleAlt":[{"title":"JTO"}],"part":{"year":"2024","pages":"e5-e6","issue":"5","text":"19(2024), 5 vom: Mai, Seite e5-e6","volume":"19","extent":"2"},"disp":"Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLCJournal of thoracic oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"508331986","language":["eng"],"origin":[{"dateIssuedDisp":"2006-","publisher":"Elsevier ; Lippincott Williams & Wilkins","dateIssuedKey":"2006","publisherPlace":"Amsterdam ; Philadelphia, Pa."}],"id":{"eki":["508331986"],"zdb":["2223437-8"],"issn":["1556-1380"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"2 S."}],"id":{"eki":["190943373X"],"doi":["10.1016/j.jtho.2024.01.020"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"May 2024"}],"name":{"displayForm":["Binghao Zhao, Longping Yao, Wenbin Ma"]}} | ||
| SRT | |a ZHAOBINGHAOSIMERTINI2024 | ||